JAMA Neurol:高强度平板运动对于帕金森病患者是否可行?

2018-01-04 吴星 环球医学

2017年12月,发表在《JAMA Neurol》上的一项2期随机临床试验,考察了高强度平板运动对新发帕金森病患者运动症状的影响。

2017年12月,发表在《JAMA Neurol》上的一项2期随机临床试验,考察了高强度平板运动对新发帕金森病患者运动症状的影响。

帕金森病是一种进行性神经系统疾病。有限的证据表明,耐力运动可改变疾病严重程度,尤其是高强度的运动。

旨在检测在未服用药物的新发帕金森病患者中,高强度平板运动的可行性和安全性,以及该运动对运动症状的效果是否需要进行3期临床试验。

运动在帕金森病中的研究(SPARX)是一项2期多中心随机临床试验,试验设立了3组,评估者对分组设盲。门诊和基于社区门诊的患者于2012年5月1日~2015年11月30日入组,首要终点评估发生在6个月时。患者的入组标准为,患有特发性帕金森病(Hoehn-Yahr分级为1级或2级),年龄在40~80岁之间,确诊时间在5年之内,运动强度不大于每周3次的中等强度,且6个月内不需要使用多巴胺能药物。通过电话总共筛查出了384例患者,其中128例患者被随机分配至以下3组中的1组:高强度运动、中等强度运动、对照。

高强度平板运动(每周4天,80%~85%最大心率;43例)、中等强度平板运动(每周4天,60%~65%最大心率;45例)、等待名单对照(40例)。共持续6个月。

可行性测量为心率标准和每周3天的运动频率的依从性和安全性。临床结局为统一帕金森病评定量表运动评分6个月的变化。

总共128例患者纳入到研究中[平均(SD)64(9)岁;年龄范围,40~80岁;73例(57.0%)为男性,108例(84.4%)为非西班牙裔白人]。高强度组运动情况为:以80.2%(95% CI,78.8~81.7)的最大心率每周运动2.8天(95% CI,2.4~3.2),中等强度组运动情况为:以65.9%(64.2~67.7)的最大心率每周运动3.2天(2.8~3.6;P=0.13)(P<0.001)。高强度组统一帕金森病评定量表运动评分的平均变化为0.3(95% CI,-1.7~2.3),常规组为3.2(1.4~5.1)(P=0.03)。与对照组相比,高强度组而非中等强度组达到了预先设定的非无效阈值。预期的肌肉骨骼不良事件不严重。

高强度平板运动对于帕金森病患者是可行和安全的。需要有效性试验来确定高强度平板运动是否会对新发帕金森病患者产生有意义的临床获益。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757413, encodeId=a0171e57413c9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Sep 23 23:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000248, encodeId=25582000248dc, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 14 23:48:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573926, encodeId=d1ca15e39266d, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604013, encodeId=39331604013df, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757413, encodeId=a0171e57413c9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Sep 23 23:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000248, encodeId=25582000248dc, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 14 23:48:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573926, encodeId=d1ca15e39266d, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604013, encodeId=39331604013df, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-05-14 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757413, encodeId=a0171e57413c9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Sep 23 23:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000248, encodeId=25582000248dc, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 14 23:48:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573926, encodeId=d1ca15e39266d, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604013, encodeId=39331604013df, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757413, encodeId=a0171e57413c9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Sep 23 23:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000248, encodeId=25582000248dc, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 14 23:48:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573926, encodeId=d1ca15e39266d, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604013, encodeId=39331604013df, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Jan 06 00:48:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-01-06 aids219